

CURRICULUM VITAE

PERSONAL INFORMATION:

Name: Robert Alan Adler, M.D.

Office Address: Chief, Endocrinology & Metabolism (111P)
Hunter Holmes McGuire Veterans
Affairs Medical Center
1201 Broad Rock Blvd.
Richmond, VA 23249
(804) 675-5424
FAX: (804) 675-5453
robert.adler@va.gov
Robert.adler@vcuhealth.org

LICENSURE:

Medical Licenses: 1972 – Maryland (Inactive)
1972 – Massachusetts (Inactive)
1973 – Virginia #0101023736
1976 – New Hampshire #5574 (Inactive)

Certification: Diplomate, National Board of Medical Examiners, 1971
Diplomate, American Board of Internal Medicine, 1974
Diplomate, American Board of Internal Medicine,
Subspecialty Certification in Endocrinology, 1975
Certified Clinical Densitometrist (ISCD), 1999
Re-certified 2003, 2008, 2013, 2018

EDUCATION:

M.D., Johns Hopkins University School of Medicine, 1970
B.A., Johns Hopkins University, 1967
Franklin & Marshall College, 1963 – 1965

MILITARY SERVICE RECORD:

Entered Active Duty, United States Army, July 9, 1973
Endocrinology Service, Walter Reed Army Medical Center, 1973 – 1974
Promotion to Major, May 29, 1974
Clinical Investigation Service and Assistant Chief, Endocrinology, Fitzsimons Army Medical Center, 1974 – 1976
Inactive Reserve, 1976 – 1980
Honorable Discharge, January 31, 1980

POSTDOCTORAL TRAINING:

Fellow in Endocrinology, Walter Reed Army Medical Center, 1973 – 1974
Fellow in Endocrinology, Massachusetts General Hospital, 1972 – 1973
Assistant Resident (Medicine) Johns Hopkins Hospital, 1971 – 1972
Intern (Medicine) Johns Hopkins Hospital, 1970 – 1971

ACADEMIC APPOINTMENTS AND OTHER EXPERIENCE:

Virginia Commonwealth University (Medical College of Virginia):
Professor of Epidemiology and Community Health 2005-
Professor of Preventive Medicine and Community Health 2002-04
Professor of Internal Medicine, 1993 –
Associate Professor of Internal Medicine, 1984 – 1993
Tenure Awarded, 1988

McGuire Veterans Affairs Medical Center:
Chief, Endocrinology and Metabolism, July 1985 –
Acting Chief of Endocrinology, December 1984 – July 1985
Assistant Chief of Endocrinology and Metabolism, July – December 1984

Dartmouth Medical School:
Adjunct Associate Professor of Medicine, 1984 – 1990
Associate Professor of Medicine 1982 – 1984
Assistant Professor of Medicine, 1976 – 1982

White River Junction Veterans Administration Medical Center:
Consultant in Endocrinology, 1976 – 1984

Dartmouth Hitchcock Medical Center:
Staff Physician, Endocrinology, 1976 – 1984

University of Colorado School of Medicine:
Clinical Instructor in Medicine, 1975 – 1976

MEMBERSHIP-SCIENTIFIC, HONORARY AND PROFESSIONAL SOCIETIES:

Endocrine Society
National Osteoporosis Foundation
American Society for Bone and Mineral Research
International Society for Clinical Densitometry
Richmond Endocrine Club

SPECIAL AWARDS AND HONORS:

Special Teaching Award, Dartmouth Medical School, 1984
Nominee for Best Teacher Award, MCV/VCU, 1994, 1995
Outstanding Teacher Award, MCV/VCU 1998 – 1999, 2014
Irby-James Award for Excellence in Clinical Teaching, VCU 2004
International Society for Clinical Densitometry – Clinician of the Year Award, 2012
American Society for Bone and Mineral Research – Shirley Hohl Service Award, 2016
Fellow, American Society for Bone and Mineral Research 2019

REVIEWING EXPERIENCE:

Journals: Journal of Clinical Endocrinology and Metabolism, Endocrinology, Molecular and Cellular Biochemistry, Archives of Internal Medicine, Life Sciences, Proceedings of the Society for Experimental Biology and Medicine, Acta Endocrinologica, Neuroendocrinology, Alcoholism: Clinical and Experimental Research, American Journal of Physiology, Thyroid, Journal of Bone and Mineral Research, NeuroImmunoModulation, Clinical Endocrinology, Journal of the American Medical Association, Journal of Endocrinology, American Journal of the Medical Sciences, Osteoporosis International, Calcified Tissue International, Consultant, NACB Thyroid Testing Guidelines, Journal of Rheumatology, Journal of Clinical Densitometry, Medical Principles and Practice (Kuwait), American Journal of Epidemiology, The Lancet, Value in Health (ISPOR journal), Lasers in Medical Science, Endocrine Practice, Controlled Clinical Trials, Annals of Internal Medicine (Outstanding Reviewer 2009, 2018), The Journal of Women's Health, Chest, Southern Medical Journal, Journal of the National Medical Association, Clinical Interventions in Aging, Nature Clinical Practice Endocrinology and Metabolism, European Respiratory Journal, Journal of the National Cancer Institute, Endocrine Research, Therapeutic Advances in Musculoskeletal Disease, Translational Research in Endocrinology and Metabolism, Sarcoidosis Vasculitis and Diffuse Lung Disease, Journal of Urology, Journal of the American Geriatrics Society, BMC Geriatrics, Arthritis Care and Research, Drugs, COPD: Journal of Chronic Obstructive Pulmonary Disease, Diabetologia, Spinal Cord, Archives of Physical Medicine and Rehabilitation, Bone Research, Endocrine, Mayo Clinic Proceedings, BMJ, European Journal of Endocrinology, Expert Review of Clinical Pharmacology, Journal of the American Medical Directors Association, The Lancet Diabetes & Endocrinology, New England Journal of Medicine.

Research Grant Proposals (Ad hoc):

Department of Veterans Affairs Merit Review Grant Program
March of Dimes Grant Program
American Federation for Aging Research
Spinal Cord Foundation
Veterans Affairs Cooperative Studies Program, Rehabilitation R&D
Jeffress Foundation
May Day Foundation

NIH Special Study Section – Prevention of Osteoporosis

NIH Study Sections: DDK – B Subcommittee, SBSR, NIAMS Special Emphasis

NIH Study Section (ad hoc) – SBDD 2003-2011

US Army Congressionally Directed Medical Research 2009, 2010, 2012

Editorial Board:

Journal of Clinical Endocrinology and Metabolism, 1988 – 1992; 2012-2018

Endocrinology and Metabolism Editor, Plexus, 1991- 1993

Journal of Clinical Densitometry, 1997-

American Journal of Physiology, Endocrinology Section, 1998 – 2001

Endocrine Research, 2008-

Journal of Bone and Mineral Research 2010-2014

Osteoporosis International 2012-2015;

Associate Editor 2015-

Section Editor, Current Osteoporosis Reports 2012-2015

Osteoporosis Subspecialty Consultant, Prescriber's Letter 2012-

Endocrine 2015-

Journal of Endocrinological Investigation 2018-

Accreditation:

Endocrinology Subspecialty Programs Pre-Reviewer, Accreditation

Council for Graduate Medical Education, 1994 – 1998

Endocrinology Subspecialty Appeals Panel, ACGME, 2000 –

RECENT COMMITTEE ASSIGNMENTS

McGuire Veterans Affairs Medical Center:

Research Committee, 2003-2006

Research Safety Subcommittee, 2003- Chair, 2006-

Department of Veterans Affairs

Endocrinology/Diabetes Field Advisory Committee 2008-2018

Chair, Male Osteoporosis Technical Advisory Panel 2007-2018

Co-Chair, Osteoporosis Field Advisory Committee 2018-

International Society for Clinical Densitometry

Scientific Advisory Committee 2003-2011

Subcommittee on using QUS in FRAX 2010-2011

Virginia Commonwealth University

Search Committee, Department of Medicine Chair 2010

Chair, Search Committee for Endocrine Division Chair 2011-2013

American Society for Bone and Mineral Research

Professional Practice Committee 2004-2011; Chair 2007-2011
Science Policy Committee (*ex officio*) 2007-2011
Atypical Femoral Fracture Task Force 2009-2015
Clinician Outreach Task Force 2009-
Co-Chair, Taskforce on ASBMR-Industry Relationships 2009-2011
Taskforce on Osteoporotic Fracture Secondary Prevention 2011-2012
Clinical Program Co-Chair ASBMR 2012 Annual Meeting 2011-2012
Strategic Planning Team 2010-
Council (elected) 2012-2015
Co-Chair, Task Force on Managing Osteoporosis Patients After Long-Term
Bisphosphonate Treatment 2013-2016
Ethics Advisory Committee 2018-, Chair 2019-

American College of Rheumatology Glucocorticoid-Induced Osteoporosis Expert Panel 2009, 2015

Osteoporosis Working Group (American Medical Association, American Academy of Family Physicians, American Academy of Orthopaedic Surgeons, American Association of Clinical Endocrinologists, American College of Rheumatology, The Endocrine Society, Physician Consortium for Performance Improvement) 2006

Endocrine Society- Osteoporosis in Men Clinical Guideline Committee (ASBMR Representative) 2009- 2012

American Dental Association Council on Scientific Affairs Advisory Committee on Medication-Associated Osteonecrosis of the Jaw 2009-2012

Panel Member, NASA Summit on the Risk for Early Onset Osteoporosis Due to Spaceflight 2010-

International Advisory Board, Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group 2011-

American Academy of Orthopaedic Surgeons Clinical Practice Guideline on Management of Hip Fractures in the Elderly (Endocrine Society Representative) 2012-2014

University of Gent, Belgium, PhD Reading Committee for Stefan Goemaere 2014

Panel Member, FDA Review of Testosterone Replacement Therapy, 2014, 2016

ASBMR Co-Chair, National Bone Health Alliance 2014-2018

Panel Member, FDA Osteoporosis Workshop, October 2015

Scientific Steering Committee, International Conference on Controversies in Vitamin D, 2016-

Speaker and Panel Member, NIH Pathways to Prevention Workshop, October 2018

Panel Member, FDA Review of Romosozumab for Osteoporosis, January, 2019

ARTICLES:

1. Burman KB, Wartofsky L, Adler RA: Hemiogenesis of the thyroid gland. *American Journal of Medicine* 58:143-146, 1975.
2. Hofeldt FD, Adler RA, Boland MJ, Block MB: Galactorrhea: What does it mean? *Rocky Mountain Medical Journal* 73:252-254, 1975
3. Adler RA, Noel GL, Wartofsky L, Frantz AG: Failure of oral water loading and intravenous hypotonic saline to suppress plasma prolactin in man. *Journal of Clinical Endocrinology and Metabolism* 41:383-389, 1975.
4. Hofeldt FD, Adler RA, Herman RH: Postprandial hypoglycemia, fact or fiction. *Journal of the American Medical Association* 233:1309, 1975
5. Wartofsky L, Dimond RC, Noel GL, Adler RA, Frantz AG, Earll JM: The effect of an oral water load on serum TSH in normal subjects and on TSH and prolactin responses to thyrotropin releasing hormone (TRH) in patients with primary hypothyroidism. *Journal of Clinical Endocrinology and Metabolism* 41:784-787, 1975.
6. McCowen KD, Adler RA, Ghaed N, Verdon TA, Hofeldt FD: Low dose radioiodide thyroid ablation in post-surgical patients with thyroid cancer. *American Journal of Medicine* 61:52-58, 1976.
7. Hofeldt FD, Weled BJ, Brown JE, Adler RA, Ghaed N, Hirata RM: "Silent Thyroiditis" versus thyrotoxicosis factitia. *Minnesota Medicine* 59: 380-382, 1976.
8. Adler RA, Corrigan DF, Wartofsky L: Hypothyroidism after X-irradiation to the neck. *Johns Hopkins Medical Journal* 138:180-184, 1976.
9. Adler RA: The evaluation of galactorrhea. *American Journal of Obstetrics and Gynecology* 127: 569-571, 1977.
10. Zwillich CW, Matthay M, Potts DE, Adler RA, Hofeldt F, Weil JW: Thyrotoxicosis: comparison of effects of thyroid ablation and beta adrenergic blockade on metabolic rate and ventilatory control. *Journal of Clinical Endocrinology and Metabolism* 46: 491-500, 1978.
11. McCowen KD, Adler RA, O'Barr TP, Hofeldt FD: Clinical implications of the flat oral glucose tolerance test. *Military Medicine* 144: 177-179, 1979.

12. Adler RA, Dophin S, Szeffler M, Sokol HW: The effects of elevated circulating prolactin in rats with hereditary hypothalamic diabetes insipidus (Brattleboro strain). *Endocrinology* 105: 1001-1006, 1979.
13. Kidd GS, Schaaf M, Adler RA, Lassman MN, Wray HL: Skeletal responsiveness in pseudo-hypoparathyroidism: a spectrum of clinical disease. *American Journal of Medicine* 68: 772-781, 1980.
14. Adler RA, Brown SJ Sokol HW: Characteristics of prolactin secretion from anterior pituitary implants. In: L'Hermitte M and Judd SJ, Eds., *Progress in reproductive biology: advances in prolactin*. Vol, 6, pp. 24-30, (Karger, Basel 1980).
15. Smith RE, Adler RA, Clark P, Brinck-Johnsen T, Tulloh ME Colton T: Thyroid function after mantle irradiation in Hodgkin's disease. *Journal of the American Medical Association* 245: 46-49, 1981.
16. North WG, Gellai M, Sokos HW, Adler RA: Demonstration that rat prolactin has no intrinsic antidiuretic activity in the rat. *Hormone Research* 15: 55-64, 1981.
17. Adler RA, Marceau M, Borst DW, Sokol HW, Culp WJ: Preparation of a biologically active rat prolactin devoid of antidiuretic activity. *Endocrinology* 110: 674-676, 1982.
18. Adler RA, Sokol HW: Glucose tolerance in rats with elevated circulating prolactin levels. *Hormone and Metabolic Research* 14: 307-310, 1982.
19. Adler RA, Sokol HW: Prolactin and growth hormone in the unstressed homozygous Brattleboro rat. In: Sokol HW and Valtin H, Eds., *The Brattleboro Rat*, *Annals of New York Academy of Science*, 394: 607-613, 1982.
20. Merlis AL, Schaiberger CL, Adler RA: External carotid-cavernous sinus fistula simulating unilateral Graves Disease. *Journal of Computer Assisted Tomography* 6: 1006-1009, 1982.
21. Adler RA, Sokol HW: Studies of anterior pituitary-grafted rats: I. Abnormal prolactin response to thyrotropin releasing hormone, clonidine, insulin and fasting. *Life Sciences* 32: 2949-2956, 1983.
22. Adler RA, Herzberg VL, Sokol HW: Studies of Anterior pituitary-grafted rats: II Normal growth hormone secretion. *Life Sciences* 32: 2957-2963, 1983.
23. Adler RA: Lower doses of thyroxine replacement for older patients. *Clinical Practice Update* 2:81-82, 1983.
24. Adler RA, Stauffer M, Gutman J, Brinck-Johnsen T: Hypercalciuria and bone changes in male hyperprolactinemic rats. In: MacLeod RM, Thorner MO, and Scapagnini U, Eds., *Prolactin-basic and clinical correlates*, Liviana Press, Padua, 385-389, 1985.

25. St.Germain DL, Adler RA, Galton VA: Thyroxine 5'-deiodinase activity in anterior pituitary glands transplanted under the renal capsule in the rat. *Endocrinology* 117: 55-63, 1985.
26. Adler RA, Herzberg VL, Brinck-Johnsen T, Sokol HW: Increased water excretion in hyperprolactinemic rats, *Endocrinology* 118: 1519-1524, 1986.
27. Moussalli C, Adler RA: Hypothalamic dysfunction from a stab wound. *Military Medicine* 151: 120-122, 1986.
28. Adler RA, Costanzo LS, Stauffer ME: Hypercalciuria in hyperprolactinemic rats: Effects of benzthiazide. *Metabolism* 35: 668-672, 1986.
29. Adler RA: The anterior pituitary-grafted rat: A valid model of chronic hyperprolactinemia. *Endocrine Reviews* 7: 302-313, 1986.
30. Costanzo LS, Smith B, Adler RA: Examination of hypercalciuria in the anterior pituitary-implanted rat. *American Journal of Physiology* 252: F916-F921, 1987.
31. Castellucci RP, Gardner DF, Haden HT, Adler RA: Autoimmune thyroiditis presenting as a systemic, febrile illness diagnosed with gallium scan and fine needle aspiration biopsy. *Southern Medical Journal* 82: 647-649, 1989.
32. Adler RA, Farrell ME, Krieg RJ, Deiss WP: Hypogonadism does not mediate calcium loss in pituitary-grafted rats. *Metabolism* 38: 805-809, 1989.
33. Barlascini CO, Schmitt JK, Adler RA: Insulin pump therapy of diabetes mellitus in quadriplegia. *Archives of Physical Medicine and Rehabilitation* 70:58-60, 1989.
35. Krieg RJ, Jr., Johnson JH, Adler RA: Growth hormone (GH) secretion in the pituitary-grafted male rat: In vivo effects of GH-releasing hormone and isoproterenol, and in vitro release by individual somatotropes. *Endocrinology* 125: 2273-2278, 1989.
36. Davee AM, Rosen CJ, Adler RA: Exercise patterns and trabecular bone density in college women. *Journal of Bone and Mineral Research* 5: 245-250, 1990.
37. Rosen CJ, Usiskin K, Owens M, Barlascini CO, Belsky M, Adler RA: T-lymphocyte surface antigen markers in osteoporosis. *Journal of Bone and Mineral Research* 5: 851-855, 1990.
38. Adler RA, Krieg RJ, Farrell ME, Deiss WP, MacLeod RM: Characterization of a new model of chronic hyperprolactinemia. *Metabolism* 40: 286-291, 1991.
39. Adler RA, Farrell ME, Deiss WP, Krieg RJ, MacLeod RM: Hypercalciuria in a new rat model of hyperprolactinemia. *Metabolism* 40: 292-296, 1991.

40. Adler RA: Osteoporosis and exercise. *Current Opinion in Orthopaedics* 2: 98-102, 1991.
41. Adler RA, Krieg RJ: Normal food intake and growth in hyperprolactinemic rats. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology* 261: R548-R552, 1991.
42. McMurtry CT, Young SC, Downs RW Adler RA: Mild vitamin D deficiency and secondary hyperparathyroidism in nursing home patients receiving adequate vitamin D. *Journal of the American Geriatrics Society* 40: 343-347, 1992.
43. Guan J-X, Spangelo BL, Judd AM, Naylor PH, Goldstein AL, Kreig RJ, Adler RA, MacLeod RM: Prolactin-secreting tumors stimulate the release of interleukin 6 from the anterior pituitary in vitro. *Progress in Neuro EndocrinImmunology* 4: 195-201, 1991.
44. Adler RA: Clinically important effects of alcohol on endocrine function. *Journal of Clinical Endocrinology and Metabolism* 75: 1531-1534, 1992.
45. Saudek CD, Duckworth WC, Veterans Affairs Study Group. The Department of Veterans Affairs Implanted Insulin Pump Study. *Diabetes Care* 15: 567-570, 1992.
46. Rosen CJ Adler RA: Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. *Journal of Clinical Endocrinology and Metabolism* 75: 1531-1534, 1992.
47. McMurtry CT, Godschalk M, Malluche HH, Geng Z Adler RA: Oncogenic osteomalacia associated with metastatic prostate carcinoma: Case report and review of the literature. *Journal of the American Geriatrics Society* 41:983-985, 1993.
48. Hobbs CJ, Plymate SR, Rosen CJ, and Adler RA: Testosterone administration increases insulin-like growth factor I (IGF-I) levels in normal men. *Journal of Clinical Endocrinology and Metabolism* 77: 776-779, 1993.
49. Adler RA, Naumann SA, Mansouri A, Krieg RJ, Latta K Sanders KM: Anti-proliferative effects of deflazacort on Nb2 lymphoma cells as quantitated by formazan production. *Life Sciences* 55: 1823-1831, 1994.
50. Adler RA, Rosen CJ: Glucocorticoids and osteoporosis, *Endocrine and Metabolism Clinics of North America* 276: 1322-1327, 1996.
51. Saudek CD, Duckworth WC, Hurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve F, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman S, Morgan NA: Comparison of the implantable insulin pump with multiple dose insulin in the treatment of non-insulin-dependent diabetes mellitus: The Veterans Affairs implantable insulin pump study. *Journal of the American Medical Association* 276: 1322-1327, 1996.

52. Rosenthal AJ, Sanders KM, McMurtry CT, Jacobs MA, Thompson DD, Gheorghiu D, Little KL, Adler RA: Is malnutrition overdiagnosed in older hospitalized patients? Association between the soluble interleukin-2 receptor and serum markers of malnutrition. *Journal of Gerontology: Medical Sciences* 53A: M81-M86, 1998.
53. Rosenthal AJ, McMurtry CT, Sanders KM, Jacobs M, Thompson DD, Adler RA: The soluble interleukin-2 receptor predicts mortality better than albumin or cholesterol in older hospitalized men. *Journal of the American Geriatrics Society* 45: 1362-1364, 1997.
54. Gunnison AF, Bowers A, Nadziejko C, Adler RA: Modulation of the inflammatory effects of inhaled ozone in rats by subcutaneous prolactin-secreting, pituitary-derived tumors. *Fundamental and Applied Toxicology* 37: 88-94, 1997.
55. Adler RA, Evani R, Mansouri A, Krieg RJ, Jr.: Relative effects of prolactin excess and estrogen deficiency on bone in rats. *Metabolism* 47: 425-428, 1998.
56. Adler RA: The diagnosis and treatment of testosterone deficiency: an overview. *Federal Practitioner* 14: (Supplement 5S): 7-11, 1997.
57. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of bone mineral density. *Journal of Clinical Endocrinology and Metabolism*: 83: 2286-2290, 1998.
58. Adler RA, Nordlie RR, Burke TS: Case Report: Increased bone mineral density in a man with known compression fractures. *Journal of Clinical Densitometry* 1: 275-278, 1998.
59. Duckworth WC, Saudek CD, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve FJ, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman MS, Morgan NA: The Veterans Affairs implantable insulin pump study: effect on cardiovascular risk factors. *Diabetes Care* 21: 1596-1602, 1998.
60. Levy JR, Gyarmati J, Lesko JM, Adler RA, Stevens W: Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. *American Journal of Physiology* 278: E892-E901, 2000.
61. Adler RA: Sex steroids and osteoporosis: The role of estrogens and androgens. *Clinics in Laboratory Medicine* 20: 549-558, 2000.
62. Levy JR, Lesko J, Krieg RJ, Adler RA, Stevens W: Leptin responses to glucose infusions in obesity-prone rats. *American Journal of Physiology* 279: E1088-1096, 2000.
63. Adler RA, Funkhouser HL, Holt CM: Utility of heel ultrasound bone density in men. *Journal of Clinical Densitometry* 4: 225-230, 2001.

64. Funkhouser HL, Adera T, Adler RA: The effect of HMG-CoA reductase inhibitors (statins) on bone mineral density, *Journal of Clinical Densitometry* 5:151-158, 2002.
65. Vieweg WVR, Adler RA, Fernandez A: Antipsychotic drugs, weight gain, and diabetes mellitus: new approaches, *Current Psychiatry* 1(8):10-19, 2002.
66. Via PS, Wamsley C, Haselbush AM, Adler RA: Osteoporosis education: Reducing risk and preventing fracture, *Federal Practitioner* 20(5):25-38, 2003.
67. Adler RA, Funkhouser HL, Petkov VI, Elmore BL, Via PS, McMurtry CT, Adera T: Osteoporosis in pulmonary clinic patients: does point of care screening predict central dual energy x-ray absorptiometry?, *Chest* 123:2012-2018, 2003.
68. Adler RA, Funkhouser HL, Petkov VI, Berger MM: Glucocorticoid-Induced Osteoporosis (GIOP) in patients with sarcoidosis, *American Journal of the Medical Sciences* 325:1, 2003.
69. Adler RA, Hochberg MC: Suggested guidelines for evaluation and treatment of glucocorticoid induced osteoporosis for the Department of Veterans Affairs, *Archives of Internal Medicine* 163:2619-2624, 2003.
70. Stern AG, de Carvalho MR, Buck GA, Adler RA, Rao TPS, Disler D, Moxley G: Association of erosive hand osteoarthritis with a single nucleotide polymorphism on the gene encoding interleukin-1 beta, *Osteoarthritis and Cartilage* 11:394-402, 2003.
71. Adler RA, Tran MT, Petkov VI: Performance of the OST screening tool for osteoporosis in American men, *Mayo Clinic Proceedings* 78:723-729, 2003.
72. Johnson SL, Petkov VI, Williams MI, Via PS, Adler RA: Improving osteoporosis management in patients with fractures, *Osteoporosis International* 16:1079-1085, 2005.
73. Adler RA, Fractures syndromes in men, *Advances in Osteoporotic Fracture Management* 3:112-117, 2005.
74. Adler RA: Osteoporosis Treatment in 2005, *Southern Medical Journal* 98:963, 2005.
75. Adler RA: The need for increasing awareness of osteoporosis in men, *Clinical Cornerstone* 8: (Supplement 3)S7-S13, 2006.
76. Adler RA: Epidemiology and pathophysiology of osteoporosis in men, *Current Osteoporosis Reports* 4:110-115, 2006.
77. Leslie WD, Adler RA, El-Hajj Fuleihan G, Hodsman AB, Kendler DL, McClung M, Miller PD, Watts NB: Application of the 1994 WHO Classification to Populations Other Than Postmenopausal Caucasian Women: The 2005 ISCD Official Position, *Journal of Clinical Densitometry* 9:22-30, 2006

78. Adler RA: Cancer treatment-induced bone loss, *Current Opinion in Endocrinology, Diabetes & Obesity* 14:442-445, 2007.
79. Lynn HS, Woo J, Leung PC, Barrett-Connor EL, Nevitt MC, Cauley JA, Adler RA, Orwoll ES, for the Osteoporosis Fractures in Men (MrOS) Study, An evaluation of osteoporosis screening tools for the The Osteoporosis Fractures in Men (MrOS) Study, *Osteoporosis International* 19:1087-1092, 2008.
80. Simonelli C, Adler RA, Blake GM, Caudill JP, Khan A, Leib E, Maricic M, Prior JC, Eis SR, Rosen C, Kendler DL: Dual energy x-ray absorptiometry technical issues: The 2007 ISCD Official Positions. *Journal of Clinical Densitometry* 11:109-122, 2008.
81. Frey ME, Kasturi G, Adler RA, Cifu DX, Qutubuddin A: Curve/Countercurve – Management of sacral insufficiency fractures. *Spine* 9:10-16, 2008.
82. Hochberg MC, Adler RA: Screening for osteoporosis in men: Comment on the American College of Physician's Clinical Guidelines, *Nature Clinical Practice: Rheumatology* 4:626-627, 2008.
83. Devogelaer J-P, Adler RA, Recknor C, See K, Warner M, Wong M, Krohn K: Relationship between baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis, *Journal of Rheumatology* 37:141-148, 2010.
84. Kasturi, G, Cifu DX, Adler RA: A review of osteoporosis, Part I: Impact, pathophysiology, diagnosis, and the unique role of the physiatrist, *PM&R* 1:254-260, 2009.
85. Saag, KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Kresge JH, Krohn K, Warner MR: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial, *Arthritis and Rheumatism* 60:3346-3355, 2009.
86. Adler RA, Hastings FW, Petkov VI: Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAXTM, *Osteoporosis International* 21:647-653, 2010.
87. Ryan CS, Petkov VI, Adler RA: Osteoporosis in men: the value of laboratory testing, *Osteoporosis International* 22:1845-1853, 2011.
88. Johnson DA, Williams MI, Petkov VI, Adler RA: Zoledronic acid treatment of osteoporosis: Effects in men, *Endocrine Practice* 16:960-967, 2010.
89. Adler RA, Favus MJ: Following bone density in patients on bisphosphonates – another perspective, *Journal of Bone and Mineral Research* 24:1647-1648, 2009.

90. Orwoll E, Miller P, Adachi J, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein R: Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study, *Journal of Bone and Mineral Research* 25:2239-2250, 2010.
91. Adler RA: Preventing the next “bone event,” *Journal of the American Geriatrics Society* 58:762-764, 2010.
92. Adler RA: Glucocorticoid-induced osteoporosis: management update, *Current Osteoporosis Reports* 8:10-14, 2010.
93. Qutubuddin A, Cifu DX, Adler RA, Carne W, Gitchel G: A pilot study of Vitamin D and balance characteristics in middle-aged, healthy individuals, *PM&R* 2:23-26, 2010.
94. Adler RA: Osteoporosis, androgen levels, and urologic care, *Journal of Urology*, 183:2122-2123, 2010.
95. Kasturi G, Adler RA: The extent of diagnosis and treatment in a Veterans Affairs population undergoing vertebral augmentation, *PM&R* 2:811-816, 2010.
96. Kasturi G, Adler RA: Osteoporosis: Non-pharmacologic management, *PM&R* 3:562-572, 2011.
97. Shane E, Burr DB, Ebeling PE, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Tet Sen H, van der Meulen MCH, Weinstein RS, Whyte M: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research, *Journal of Bone and Mineral Research* 25:2267-2294, 2010.
98. Adler RA: Osteoporosis in Men: What has Changed? *Current Osteoporosis Reports*, 9:31-35, 2011.
99. LaFleur J, Nelson RE, Yao Y, Adler RA, Nebeker JR: Validated risk rule using computerized data to identify males at high risk for fracture, *Osteoporosis International* 23:1017-1027, 2012.
100. Adler RA: Management of osteoporosis in men on androgen deprivation therapy, *Maturitas* 68:143-147, 2011.
101. Adler RA: Osteoporosis in prostate disease, *Current Medical Literature-Rheumatology* 30:1-7, 2011.

102. Hansen KE, Fink H, Minisola S, Wilson HA, Zapalowski C, Adler RA: Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis, *Journal of Bone and Mineral Research* 26:1989-1996, 2011.
103. Kasturi G, Adler RA: Mechanical means to improve bone strength: ultrasound and vibration, *Current Rheumatology Reports* 13:251-256, 2011.
104. Adler RA: Osteoporosis in men: insights for the clinician, *Therapeutic Advances in Musculoskeletal Disease* 3:191-200, 2011.
105. Adler RA, Hochberg MC: Glucocorticoid-induced osteoporosis in men, *Journal of Endocrinological Investigation* 34:481-484, 2011.
106. Bockman RS, Zapalowski C, Kiel DP, Adler RA: Commentary on calcium supplements and cardiovascular disorders, *Journal of Clinical Densitometry* 15:130-134, 2012.
107. Adler RA, Gill RS: Clinical utility of denosumab for the treatment of bone loss in men and women, *Clinical Interventions in Aging* 6:119-124, 2011.
108. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H: Managing the care of patients receiving antiresorptive therapy for the prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *Journal of the American Dental Association* 142:1243-1251, 2011.
109. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmaly JR, Koka S, Migliorati CA, Ristic H for the American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: recommendations from the American Dental Association Council on Scientific Affairs. www.ada.org/sections/professionalResources/pdfs/topics_aronj_report.pdf, 2011.
110. Dolbow DR, Gorgey AS, Daniels JA, Adler RA, Moore JR, Gater, DR Jr.: The effects of spinal cord injury and exercise on bone mass: a literature review, *NeuroRehabilitation* 29:261-269, 2011.
111. Moayyeri A, Adams JE, Adler RA, Blake GM, Krieg M-A, Hans D, Compston J, Lewiecki EM. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis, *Osteoporosis International* 23:143-153, 2012.
112. Adler RA, Bates D, Dell R, LeBoff MS, Majumdar SR, Saag KG, Solomon D, Suarez-Almazor M: Systems-based approaches to osteoporosis and fracture care: policy and research recommendations from the workgroups, *Osteoporosis International* 22(Suppl3): 495-500, 2011.
113. Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg M-A, Masri BK, Lorenc

RR, Bauer DC, Blake GM, Josse RG, Clark P, Khan AA, FRAX® Position Development Conference Members: Official positions for FRAX® bone mineral density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®, *Journal of Clinical Densitometry* 14:226-236,2011.

114. Adler RA: Secondary fracture prevention, *Current Osteoporosis Reports*, 10:22-27, 2012.

115. Adler RA: Osteoporosis in men, *Current Medical Literature-Rheumatology* 31:1-7, 2012.

116. Adler RA: Laboratory testing for secondary osteoporosis evaluation, *Clinical Biochemistry* 45:894-900, 2012.

117. Adler RA, Semla T, Cunningham F, Pogach L: The VHA male osteoporosis program: a national model for bone health, *Federal Practitioner* 29:31-37, 2012.

118. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, Finkelstein JS: Osteoporosis in men: An Endocrine Society Clinical Practice Guideline, *Journal of Clinical Endocrinology and Metabolism* 97:1802-1822, 2012.

119. Adler RA, Finkelstein J: Patient guide to osteoporosis in men. *Journal of Clinical Endocrinology and Metabolism* 97:39A-40A, 2012.

120. Orwoll ES, Adler RA, Amin S, Binkley N, Lewiecki EM, Petak SM, Shapses SA, Sinaki M, Watts NB, Sibonga JD: Skeletal health in long-duration astronauts: Nature, Assessment and Management Recommendations from the 2010 NASA Bone Summit, *Journal of Bone and Mineral Research* 28:1243-1255, 2013.

121. Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, Miller PD, Tanner SB, Randall S: Osteoporosis update from the 2012 Santa Fe Bone Symposium, *Journal of Clinical Densitometry*, 16:584-600, 2013.

122. Gorgey AS, Poarch H, Adler RA, Dolbow DR, Gater DR: Femoral bone marrow adiposity and cortical bone cross-sectional area in men with motor complete spinal cord injury, *PM&R* 5:939-948, 2013.

123. Adler RA: Osteoporosis in men: recent progress, *Endocrine* 44:40-46, 2013.

124. Dolbow JD, Dolbow DR, Gorgey AS, Adler RA, Gater DR: The effects of aging and electrical stimulation exercise on bone after spinal cord injury. *Aging and Disease*, 4:141-153, 2013.

125. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Tet Sun H, van der Meulen MCH, Weinstein RS, Whyte MP: Atypical subtrochanteric and diaphyseal

femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research, *Journal of Bone and Mineral Research*. *Journal of Bone and Mineral Research* 29:1-24, 2014.

126. Sealand R, Razavi C, Adler RA: Diabetes mellitus and osteoporosis, *Current Diabetes Report* 13:411-418, 2013.

127. Adler RA: Prostate cancer treated with androgen deprivation therapy has consequences for bone. *Endocrine* 45:339-340, 2014.

128. Siris E, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes , Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB. The clinical diagnosis of osteoporosis: a consensus report of the National Bone Health Alliance Working Group, *Osteoporosis International* 25:1439-1443, 2014.

129. Adler RA: Osteoporosis in men: a review. *Bone Research* 2:14001, 2014; doi:10.1038/boneres.2014.1.

130. Demarest SP, Gill RS, Adler RA: Opioid endocrinopathy, *Endocrine Practice* 21:190-198, 2015.

131. Mazziotti G, Maffezzoni I, Doga M, Hofbauer LC, Adler RA, Giustina A: Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone-active drugs, *Bone* 67: 175-180, 2014.

132. LaFleur J, DuVall SL, Willson T, Ginter T, Patterson O, Cheng Y, Knippenberg K, Hayden C, Adler RA, Curtis JR, Agodoa I, Stolshek B, Nelson RE: Analysis of osteoporosis treatment patterns and outcomes among postmenopausal veterans, *Bone* 78:174-185, 2015.

133. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR: Glucocorticoid exposure and fracture risk in patients with new onset rheumatoid arthritis, *Osteoporosis International* 27:3239-3249, 2016.

134. Binkley N, Adler R, Bilezikian JP: Osteoporosis diagnosis in men: The T-score controversy revisited, *Current Osteoporosis Reports* 12:403-409, 2014.

135. Colon-Emeric C, Pieper CF, Grubber J, Van Scoyoc L, Schnell ML, Van Houtven CH, Pearson M, LaFleur J, Lyles KW, Adler RA: Correlation of hip fracture with other fracture types: toward a rational composite hip fracture endpoint, *Bone* 81:67-71, 2015.

136. Brox, WT, Roberts KC, Taksali S, Wright DG, Wixted JJ, Tubb CC, Patt JC, Templeton KJ, Dickman E, Adler RA, Macaulay WB, Jackman JM, Annaswamy T, Adelman AM, Hawthorne CG, Olson SA, Mendleson DA, LeBoff MS, Camacho PA, Jevsevar D, Shea KG, Bozic KJ, Shaffer W, Cummins D, Murray JN, Donnelly P, Shores P, Woznica A, Martinez Y, Boone C, Gross L, Sevarino K: The American Academy of Orthopaedic Surgeons evidence-

based guideline on management of hip fractures in the elderly, *J Bone Joint Surg Am* 97:1196-1199, 2015. Full guideline: www.aaos.org/research/guidelines/HipFxGuideline_rev.pdf

- .
137. Adler RA, El Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE: Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 31:16-35, 2016.
138. Adler RA: Duration of anti-resorptive therapy for osteoporosis. *Endocrine* 51:222-224, 2016.
139. Adler RA: Osteoporosis Treatment: Complexities and Challenges, *J Endocrinol Invest* 39:719-720, 2016.
140. Moore PD, Gorgey AS, Wade RC, Khalil RE, Lavis TR, Khan R, Adler RA: Neuromuscular electrical stimulation and testosterone did not influence heterotopic ossification size after spinal cord injury. *World J Clin Cases* 4:172-176, 2016.
141. Gorgey AS, Moore PD, Wade RC, Gill RS, Lavis TR, Adler RA: Intramedullary femoral fixation attenuates testosterone action on muscle size in a person with spinal cord injury, submitted for publication.
142. Williams M, Harris, E, Kilpatrick D, Adler RA, Wan, W, Chang M, Hagan M, Moghanaki D: Prostate radiotherapy effects on testosterone levels: an empirical investigation, *J Radiation Oncology* doi.10.1007/s13566-019-0375-1, 2019
- .
143. Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A: Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/Vitamin D axes, treatment options and guidelines, *Endocrine* 54:603-611, 2016.
144. Adler RA: Bisphosphonates and atypical femoral fractures, *Curr Opin Endocrinol Diabetes* 23:430-434, 2016.
145. Adler RA: Risk factors for osteoporosis 2000-2012. *Endocrine* 55:664-665, 2017.
146. Gorgey AS, Khalil RE, Gill R, O'Brien LC, Lavis T, Castillo T, Cifu DX, Savas J, Khan R, Cardozo C, Lesnfsky EJ, Gater DR, Adler RA: Effects of testosterone and evoked resistance exercise after spinal cord injury (TEREX-SCI): study protocol for a randomized controlled trial, *BMJ open*, Apr 4;7(4)e014125, 2017.
147. Lewiecki EM, Wright NC, Curtis JR, Siris E, Gagel R, Saag KG, Singer AJ, Steven PM, Adler RA: Hip fracture trends in the United States, 2002 to 2015, *Osteoporos Int* 29:717-722, 2018.

148. Gorgey AS, Moore PD, Wade RC, Gill RS, Lavis T, Adler RA: Disruption in bone marrow fat may attenuate testosterone action on muscle size after spinal cord injury. A case report. *European Journal of Physical and Rehabilitation Medicine* 53:625-629, 2017.
149. Beal C, Gorgey A, Moore P, Wong N, Adler RA, Gater G: Higher dietary intake of Vitamin D may influence total cholesterol and carbohydrate profile independent of body composition in men with chronic spinal cord injury. *Journal of Spinal Cord Medicine*, 16:1-12, 2017.
150. Adler RA: Glucocorticoid Induced Osteoporosis and the New ACR Guideline, *Clinical Reviews in Bone and Mineral Metabolism* 15:123-127, 2017.
151. Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Van Houtven C, LaFleur J, Colon-Emeric C: Clinical fractures among older men with diabetes are mediated by microvascular and macrovascular complications. *Journal of Clinical Endocrinology and Metabolism* 103: 281-287, 2018.
152. Nightingale TE, Moore P, Harman J, Khalil R, Gill RS, Castillo T, Adler RA, Gorgey AS: Body composition changes after testosterone replacement therapy following spinal cord injury and aging. A Mini Review, *Journal of Spinal Cord Medicine* 41:624-636, 2018.
153. Hall RK, Sloane R, Peiper C, Lyles K, Van Houtven C, LaFleur J, Adler R, Colon-Emeric C. Competing risks of fracture and death in older adults with chronic kidney disease, *J Am Geriatr Soc* 66:532-538, 2018.
154. Adler RA: Atypical femoral fractures: Risks and benefits of long term treatment of osteoporosis with anti-resorptive therapy, *Eur J Endocrinol* 178:R81-R87, 2018.
155. Adler RA: Glucocorticoid-Induced osteoporosis: Short-term and long-term management. *Current Opinion in Endocrine and Metabolic Research*, 3:38-41,2018.
156. Adler RA: Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients, *Journal of Clinical Densitometry* 20:20-24, 2019.
157. Colon-Emeric CS, Pieper CF, Van Houtven CH, Grubber J, Lyles KW, LaFleur J, Adler RA: Limited osteoporosis screening effectiveness due to low treatment rates in a national sample of older men, *Mayo Clin Proc* 93:1749-1759, 2018.
158. Gorgey AS, Ciriigliaro CM, Bauman WA, Adler RA: Estimates of the precision of regional and whole body composition by dual-energy x-ray absorptiometry in persons with chronic spinal cord injury. *Spinal Cord* 56:987-995, 2018.
159. Adler RA: Practical issues in Vitamin D replacement. *Front Horm Res* 50:66-71, 2018.

160. Adler RA: Update on osteoporosis in men. *Best Pract Res Clin Endocrinol Metab* 32:759-772, 2018.
161. Ebeling PR, Adler R, Jones G, Liberman UA, Mazziotti G, Minisola S, Munns CF, Pittas AG, Giustina A, Bilezikian JP, Rizzoli R: Therapeutics of Vitamin D, *Eur J Endocrinol* 179:R239-R259, 2018.
162. Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR: Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions, *J Bone Miner Res* 33:1881-1888, 2018.
163. Abilmona SM, Sumrell RM, Gill RS, Adler RA, Gorgey AS: Serum testosterone levels may influence body composition and cardiometabolic healthy in men with spinal cord injury. *Spinal Cord* 57:229-239, 2019.
164. Solimeo, SL, McCoy K, Reisinger HS, Adler RA, Sarazin MV: Factors associated with osteoporosis care of men hospitalized for hip fracture. *JBMR Plus* 3:e0198, 2019.
165. Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP: Controversies in Vitamin D: Summary statement from an international conference. *J Clin Endocrinol Metab* 104:234-240, 2019.
166. Williams M, Harris E, Kilpatrick D, Adler RA, Wan W, Chang M, Hagan M, Moghanaki D: Prostate radiotherapy effects on testosterone levels: an empirical investigation. *J Radiat Oncol* 8:81-87, 2019.
167. Gorgey AS, Khalil RE, Gill R, Gater DR, Lavis TD, Cardozo CP, Adler RA: Low-dose testosterone and evoked resistance exercise after spinal cord injury (TEREX-SCI) on cardio-metabolic risk factors: an open-label randomized clinical trial, *J Neurotrauma*, 36:2631-2645, 2019.
168. Gorgey A, Khalil RE, Davis JC, Carter W, Gill R, Rivers J, Khan R, Goetz L, Castillo T, Lavis T, Sima A, Lesnefsky E, Cardozo C, Adler RA: Skeletal muscle hypertrophy and attenuation of cardio-metabolic risk factors (SHARC) using functional electrical stimulation-lower extremity cycling in persons with spinal cord injury. *Trials* 20:526, 2019.
169. Lee RH, Sloan R, Peiper C, Lyles KW, Adler RA, Van Houtven C, LaFleur J, Colon-Emeric C: Glycemic control and insulin treatment alter fracture risk in older men with type 2 diabetes mellitus. *J Bone Miner Res* 34:2045-2051, 2019.
170. Ogunwale AN, Colon-Emeric CS, Sloane R, Adler RA, Lyles KW, Lee RH: Acetylcholinesterase inhibitors are associated with reduced fracture risk among older veterans with dementia. *J Bone Miner Res* 35:440-445, 2020.
171. Gorgey AS, Abilmona SM, Sima A, Khalil RE, Khan R, Adler RA: A secondary analysis of testosterone and electrically evoked resistance training versus testosterone only (TEREX-

SCI) on untrained muscles after spinal cord injury: a pilot randomized clinical trial. *Spinal Cord* 58:299-308, 2020.

172. Conley RB, Adib G, Adler RA, Akesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman-Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kuzma M Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N Napoli N, Oleginski RP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP. Secondary fracture prevention: Consensus clinical recommendations from a Multistakeholder Coalition. *J Bone Miner Res* 35:36-52, 2020.

173. Gorgey AS, Graham ZA, Chen Q, Rivers J, Adler RA, Lesnefsky EJ, Cardozo CP: Sixteen weeks of testosterone with or without evoked resistance training on protein expression, fiber hypertrophy and mitochondrial health after spinal cord injury, accepted for publication, *Journal of Applied Physiology*, 2020.

174. Giustina A, Adler RA, Binkley N, Bollerslev J, Bouillon R, Dawson-Hughes B, Ebeling PR, Feldman D, Formenti AM, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP: Consensus statement from 2nd International Conference on Controversies in Vitamin D. *Rev Endocr Metab* 21:89-116, 2020.

175. Holman ME, Chang G, Ghatas MP, Saha PK, Zhang X, Khan MR, Sima AP, Adler RA, Gorgey AS: Bone and non-contractile soft tissue changes following open-kinetic-chain resistance training and testosterone replacement in spinal cord injury: an exploratory study, in press, *Osteoporosis International* 2020.

176. Adler RA: Update on rare adverse events from osteoporosis therapy and bisphosphonate drug holidays, in press, *Endocrine Clinics of North America*, 2021.

177. Giustina A, Bouillon R, Binkley N, Sempros C, Adler RA, Bollerslev J, Dawson-Hughes B, Ebeling PR, Feldman D, Heijboer AC, Jones G, Kovacs CS, Lazaretti-Castro M, Lips P, Marcocci C, Minisola S, Napoli N, Rizzoli R, Scragg R, White JH, Formenti A, Bilezikian JP. Controversies in Vitamin D: Proceedings from the 3rd International Conference, *JBMR Plus* 12(4):e10417, 2020.

178. Narla R, Adler RA: Osteoporosis care amidst the prolonged pandemic. In press, *Journal of Endocrinological Investigation*, 2021.

ABSTRACTS:

Edgar PJ, Prout TE, Adler RA, Friedlander B: Studies in vitro and in man of the Effects of aminophylline on insulin, fatty acids and glucose. *Clinical Research* 17: 588, 1969.

Wartofsky L, Dimond RC, Noel GL, Adler RA, Earll JM: Failure of T3 to block TSH responses to TRH in normal subjects and patients with primary hypothyroidism. Abstracts of 50th Meeting of the American Thyroid Association, Endocrinology 93(Suppl):T-2, 1974.

McCowen KD, Hofeldt FD, Ghaed N, Adler RA, Verdon TA: Low dose radioiodine thyroid ablation in post-surgical thyroid cancer patients. Journal of Nuclear Medicine 16: 549, 1975.

Adler RA, Bergin JJ and O'Barr TP: Clinical use of serum thyrotropin radioimmunoassay: The low thyroid reserve syndrome. Rocky Mountain Medical Journal 72:533, 1975.

Adler RA, Hofeldt FD, Ward N, O'Barr TP: Continuous insulin infusion for the treatment of diabetic ketoacidosis. Rocky Mountain Medical Journal 72:539, 1975.

Zwillich C, Matthay M, Potts D, Hofeldt F, Adler RA, Weil JV: The role of propranolol in treating the beta sympathetic mediated abnormalities of thyrotoxicosis. Clinical Research 25: 305A, 1977.

Plymate SR, Hofeldt F, Adler RA: Determinants of glucagons response in reactive hypoglycemia. Clinical Research 25:305A, 1977.

Smith RE, Adler RA, Mulherin P, Brinck-Johnsen T, Colton T, Tulloh ME: Post-irradiation thyroid function (TF) in Hodgkin's disease (HD). Clinical Research 25: 667A, 1977.

Smith RE, Adler RA, Mulherin P, Brinck-Johnsen T, Tulloh ME, Colton T: Thyroid function (TF) following mantle irradiation (RT) in Hodgkin's Disease (HD). Proceedings of the American Society of Clinical Oncology, April 1978.

Adler RA, Dolphin S, Sokol HW: Does endogenous prolactin have antidiuretic activity? Endocrinology 102: (Suppl): 552A, 1978.

Sokol HW, Adler RA, Douple EB: Water diuresis in rats bearing MtT-F4 pituitary tumor cells which produce prolactin (PRL). Abstracts of 6th New England Endocrine Conference, October 1978.

North WG, Gellai M, Sokol HW, Adler RA: Rat prolactin has no intrinsic anti-diuretic activity in the rat. Endocrinology 104(Suppl): 881A, 1979.

Adler RA, Dolphin S, Sokol HW: Improved glucose tolerance in hyperprolactinemic rats. Diabetes 28: 228A, 1979.

Adler RA, Turco JH, Roberts E, Baird S, Beisswenger PJ: Radiation-associated thyroid carcinoma: lower incidence in New Hampshire. Clinical Research 27: 572A, 1979.

Adler RA, Dolphin S, Sokol HW: Chronic hyperprolactinemia does not elevate serum glucose in rats, Abstracts of Sixth International Congress of Endocrinology, Melbourne, Australia, (#862), 1980.

Adler RA, and Sokol HW: Characteristics of prolactin secretion from anterior pituitary implants, Abstracts of workshop "Prolactin, 1980 and Beyond", Adelaide, Australia, 1980.

Adler RA, MacLaughlin J, Holick MF: the effects of hyperprolactinemia on calcium absorption. *Clinical Research* 28: 383A, 1980.

Adler RA: Effects of fasting and TRH in hyperprolactinemic and normal rats. *Endocrinology* 108(Suppl): 543A, 1981.

Marceau M, Adler RA, Sokol HW: Is prolactin involved in mammalian water balance? *Endocrinology* 108(Suppl): 558A, 1981.

Adler RA, Sokol HW: Chronic hyperprolactinemia increases water excretion in rats. *Clinical Research* 29: 664A, 1981.

Herzberg VL, Adler RA: Renal prolactin binding in chronically hyperprolactinemic rats. *Endocrinology* 110(suppl): 1125A, 1982.

Adler RA, Sokol HW: Chronic hyperprolactinemia increases water excretion in rats. *Clinical Research* 30: 267A, 1982.

Adler RA, Herzberg VL, Brinck-Johnsen T, Sokol HW: Is prolactin an adrenocorticotrophic hormone? *Clinical Research* 30: 683A, 1982.

Adler RA, Brinck-Johnsen T, Herzberg VL, Sokol SW: Glucocorticoid secretion in hyperprolactinemic rats. *Clinical Research* 31: 268A, 1983.

Adler RA, Brinck-Johnsen T, Herzberg VL, Sokol HW: Prolactin-associated corticosterone secretion in rats. *Endocrinology* 112(Suppl): 773A, 1983.

St. Germain DL, Adler RA, Galton VA: Pituitary transplantation markedly alters thyroxine 5'-deiodinase activity. *Clinical Research* 31: 680A, 1983.

St Germain DL, Adler RA, Galton VA: Pituitary transplantation results in marked alterations in thyroxine 5'-deiodinase activity. *Clinical Research* 32: 274A, 1984.

Adler RA, Stauffer M, Gutman J, Brinck-Johnsen T: Hypercalciuria and bone changes in male hyperprolactinemic rats. *Proceedings of IV International Congress of Prolactin*, Abstract #137, 1984.

Adler RA, Taylor DR, Ceresia MG, Stauffer ME: Effects of benzthiazide on hypercalciuria in hyperprolactinemic rats. *Endocrinology* 116(Suppl): 171A, 1985.

Costanzo LS, Adler RA: Chronic prolactin (PRL) excess causes hypercalciuria: A direct renal effect. American Society of Nephrology, 18th Annual Meeting, A-CA-8, 1985.

Conrad KP, Brinck-Johnsen T, Adler RA: Evidence that chronic hyperprolactinemia increases renal hemodynamics. Clinical Research 34: 592A, 1986.

Rosen CJ, Levy LJ, Adler RA: Factors associated with bone loss in hyperthyroidism, Abstracts of the American Thyroid Association Annual Meeting, Phoenix, Arizona, September, 1986, #23, p. T-12.

Adler RA, Deiss WP: Hypogonadism does not mediate calcium loss in hyperprolactinemic rats. Clinical Research 35: 392A, 1987.

Rosen CJ, Adler RA: Prolactin levels predict bone mineral content in hyperprolactinemic women. Endocrinology 120 (Suppl): 406A, 1987.

Rosen CJ, Owens M, Adler RA: Altered lymphocyte subsets in postmenopausal osteoporosis. Journal of Bone and Mineral Research 2 (Suppl): 229A, 1987.

Adler RA, Farrell ME, Deiss WP: Effects of gonadal status and dietary calcium on the hypercalciuria of female hyperprolactinemic rats. Endocrinology 122 (Suppl): 629A, 1988.

Rosen CJ, Adler RA: Longitudinal evaluation of lumbar spine absorptiometry in normal postmenopausal women. Clinical Research 37 (Suppl): 460A, 1989.

Adler RA, Krieg RJ, Farrell ME, Deiss WP: Hypercalciuria in a new model of chronic hyperprolactinemia. Endocrinology 124 (Suppl): 1511A, 1989.

Schmitt JK, Adler RA, Ha CY, Hussey RW: Diabetes mellitus in the spinal cord injury patient. American Paraplegia Society 1990.

McMurtry CT, Downs RW, Adler RA: Vitamin D metabolite status of elderly male veterans in a Virginia nursing home. American Geriatrics Society, 1990.

Adler RA, Watterson KJ, Turner AR, Deiss WP: Calcitropic hormones in hyperprolactinemic hypercalciuria. Endocrinology 126 (Suppl) 1176A, 1990.

McMurtry CT, Young SE, Adler RA, Downs RW: Mild Vitamin D deficiency and secondary hyperparathyroidism in nursing home patients receiving adequate Vitamin D intake. Journal of Bone and Mineral Research 5 (Suppl) 2: 725A, 1990.

Adler RA, Watterson KJ, Levy JR: The effect of estradiol on prolactin gene expression in ovariectomized rats bearing the MMQ tumor. Endocrinology, 128 (Suppl): 1454A, 1991.

McMurtry CT, Adler RA: Oncogenic osteomalacia associated with metastatic prostate carcinoma in an elderly male with multiple fractures. American Geriatrics Society, 1991.

Rosen CJ, Hunter S, Adler RA: Cyclic etidronate and Type II osteoporosis in elderly women. Journal of Bone and Mineral Research 6 (Suppl): S280, #785, 1991.

Rosen CJ, Adler RA: Longitudinal changes in lumbar bone mass following treatment of thyrotoxicosis. Endocrinology 130 (Suppl): 1539A, 1992.

VA Study Group: Veterans Affairs Implantable Insulin Pump Study: Study Design, Baseline Characteristics. Diabetes 43 (Suppl 1): 1539A, 1992.

VA Study Group: Veterans Affairs Implantable Insulin Pump Study: Mean Glycemia and Hypoglycemia. Diabetes 43 (Suppl 1): 61A, #194, 1994.

VA Study Group: Veterans Affairs Implantable Insulin Pump (IIP) Study: Comparison of Effects of Implantable Pumps and Multiple Insulin Injections on Metabolic and Physiological Parameters. Diabetes 43 (Suppl 1): 61A, #195, 1994.

Rosenthal A, Sanders KM, Adler RA, Jacobs M, McMurtry CT, Gheorghiu D, Little K: Misdiagnosing malnutrition: Are we treating immune activation with nutritional supplements? American Geriatrics Society, 1995.

Adler RA, Evani R, Mansouri A, Krieg RJ: Effects of mild hyperprolactinemia in ovariectomized rats. Endocrine Society Annual Meeting, #P1-26, 1995.

Adler RA, McMurtry CT, Plymate SR, Iranmanesh A, Rosen CJ: Determinants of bone mineral density in unselected older hypogonadal men. American Society for Bone and Mineral Research, 1995.

Adler RA, McMurtry CT, Plymate SR, Merriam GR, Iranmanesh A, Anderson RJ, Orwoll ES: Low serum testosterone is common in older, ambulatory men. American Society for Bone and Mineral Research, 1995.

McMurtry CT, Adler RA: Anticonvulsant osteomalacia: variable response to Vitamin D supplementation. American Society for Bone and Mineral Research, 1995.

Rosenthal A, Sanders KM, Adler RA, Jacobs M, McMurtry CT, Gheorghiu D, Little K: Soluble IL-2 receptor predicts mortality in aged men on a geriatric rehabilitation unit. American Geriatrics Society, 1996.

Adler RA, Naumann SA, Mansouri A: Prolactin stimulates proliferation of prolactin-secreting pituitary tumor cells. Endocrine Society Annual Meeting #P1-674, 1996.

Adler RA, McMurtry CT, Christmas C, Plymate SR, Iranmanesh A, Rosen CJ: IGF-1 and IGF-BP3 in older men: Relationship with gonadal function and bone mineral density. International Pituitary Congress, 1996.

Levy JR, Heuman DM, Pandak WM, Vlahcevic ZR, Adler RA, Stevens SR: Modulation of bile acids within enterohepatic circulation regulates *ob* gene expression. American Diabetes Association, 1997.

Adler RA, Rosenthal AJ, Rosen CJ: Longitudinal study of “normal” middle-aged men (academic physicians): Correlation of BMD with IGF-BP3 and BMI. American Society for Bone and Mineral Research, 1998.

Adler RA, Berger MM: Glucocorticoid-induced osteoporosis in sarcoidosis: What is the standard of care. 1st International Congress Glucocorticoid-Induced Osteoporosis, Gardone Riviera, Italy, Osteoporosis International 9: Suppl 1, 1999.

Adler RA, Lesko JM, Holt CM, Berger MM: Osteoporosis in sarcoidosis: study of prospective and referred patients. American Society for Bone and Mineral Research, #SU051, p.S444, 1999.

Kurland E, Rackoff PJ, Pochenkova M, Spotila LD, Naylor J, Rogers J, Witte S, Adler RA, Bilezikian JP, Rosen CJ: IGF-I and bone mass osteoporotic and healthy families: evidence for heritable determinants of the IGF-I phenotype and their relationship to bone. American Society for Bone and Mineral Research. #SA090, p.S331, 1999.

Adler RA, Funkhouser HL, Holt CM, Berger MM: Bone markers and other predictors of osteoporosis in patients with sarcoidosis. The Endocrine Society Annual Meeting, W-438, #1699, p.412, 2000.

Adler RA, Funkhouser HL, Holt CM: Utility of heel ultrasound BMD in men, American Society for bone and Mineral Research, #M305, 2000.

Adler RA, Funkhouser HL, Holt CM, Berger MM: Glucocorticoid-induced osteoporosis (GIOP) in patients with sarcoidosis. 2nd International Congress, Glucocorticoid Induced Osteoporosis, p.18, 2001.

Via PS, Ellis A, Wamsley-Morris C, Adler RA: Outcomes of an integrated osteoporosis education program, #P3-691, The Endocrine Society Annual Meeting, 2001.

Adler RA, Funkhouser HL, McMurtry CT, Elmore B, Bechard D, Holt CM: Can heel ultrasound plus a questionnaire predict osteoporosis in pulmonary clinic patients? American Society for Bone and Mineral Research, #SU156, 2001.

Tran M, Petkov VI, Williams MI, Via P, Holt CM, Adler RA: Can heel ultrasound plus a questionnaire predict osteoporosis in rheumatology clinic patients? International Society for Clinical Densitometry, 2002.

Via PS, Petkov VI, Adler RA: Quality of life in veteran men with osteoporosis. Endocrine Society Annual Meeting, #P1-713, 2002.

Novy AM, Sugerman HJ, Wofe LG, Kellum JM, Demaria EJ, Adler RA, Downs RW, Biskobing DM: Higher prevalence of hypocalcemia in men than women after gastric bypass surgery for obesity. Endocrine Society Annual Meeting, #P2-559, 2002.

Tran MT, Petkov VI, Holt CM, Williams MI, Adler RA: Can heel ultrasound bone mineral density plus a questionnaire predict osteoporosis in rheumatology patients? American Society for Bone and Mineral Research, M113, 2002.

Adler RA, Tran MT, Petkov VI: Concordance of heel quantitative ultrasound and central DXA in patients taking different forms of glucocorticoids. American Society for Bone and Mineral Research, M112, 2002.

Adler RA, Tran MT, Petkov VI: The OST screening tool is valid in American men. American Society for Bone and Mineral Research, M305, 2002.

Stern AG, Petkov VI, Disler D, Carlson P, Rosen CJ, Holt C, Nestler J, Adler RA: Bone mineral density in primary hand osteoarthritis: comparison between erosive and non-erosive hand osteoarthritis, International Society for Clinical Densitometry, 2003.

Stern AG, Petkov VI, Disler D, Carlson P, Rosen CJ, Holt C, Nestler J, Adler RA: Predictors of low bone mineral density in women with primary hand osteoarthritis. International Society for Clinical Densitometry, 2003.

Sicat JM, Petkov V, Adler RA, Levy JR: The incidence of ARB induced angioedema in patients with previous ACE inhibitor induced angioedema at the McGuire VA Hospital, American Diabetes Association Annual Meeting 2003

Johnson SL, Petkov VI, Via PS, Williams MI, Adler RA: Diagnosing low bone mass in fracture patients. Endocrine Society Annual Meeting, #P2-496, 2003.

Wamsley CJ, Via PS, Petkov VI, Adler RA: Fall prevention and recognition of home health hazards, Endocrine Nurses Society Annual Meeting, 2003.

Adler RA, Williams MI, Gordon MM, Johnson SL, Petkov VI: Instituting GIO Guidelines: Baseline Data, Third International Congress on Glucocorticoid Induced Osteoporosis, Turin, Italy, March 2003.

Adler RA, Williams MI, Gordon M, Petkov VI: Prevention of osteoporosis in patients treated chronically with oral glucocorticoids: comparison with guidelines. American Society for Bone and Mineral Research, #SU375, 2003.

Williams MI, Petkov VI, Johnson SL, Wright S, Tran MT, Adler RA: Applying the osteoporosis self-assessment tool (OST) in primary care practices uncovers osteoporosis in men: preliminary report. American Society for Bone and Mineral Research, #SA314, 2003.

Johnson SL, Petkov VI, Williams MI, Via P, Adler RA: Prediction of fracture risk using the osteoporosis self-assessment tool (OST). American Society for Bone and Mineral Research, #M278, 2003.

Adler RA, Williams MI, Petkov VI: Concordance of femoral neck and total hip. International Society for Clinical Densitometry #70, 2004.

Samaropoulos X, Adera T, Adler RA, Petkov VI: Prediction of fractures using OST. International Society for Clinical Densitometry #73, 2004.

Wamsley C, Via PS, Petkov VI, Adler RA: Effects of education on fall prevention actions. International Society for Clinical Densitometry #74, 2004.

Petkov VI, Williams MI, Adler RA: Screening for osteoporosis in men: Heel QUS vs. OST. International Society for Clinical Densitometry #71, 2004.

Petkov VI, Via PS, Adler RA: Screening men for osteoporosis by heel ultrasound bone densitometry: female vs. male normative database. Endocrine Nurses Society Annual Meeting, 2004, #P1-586.

Petkov, VI, Williams MI, Via PS, Hodson T, Adler RA: Dual energy x-ray absorptiometry (DXA) of the forearm in men: radius versus total, American Society for Bone and Mineral Research, #SU-125, 2004.

Williams, MI, Petkov, VI, Biskobing DM, Adler RA: The osteoporosis self-assessment tool (OST) leads to increased osteoporosis evaluation and therapy in men. American Society for Bone and Mineral Research, #SU-482, 2004.

Griffin EN, Petkov VI, Williams MI, Adler RA: Improving compliance with oral bisphosphonate therapy in a pharmacist-managed osteoporosis clinic. American Society for Bone and Mineral Research, #M-436, 2004.

Adler RA, Petkov VI, Via PS, Williams MI: Screening men 70 years and older for osteoporosis: are we missing osteoporosis in younger men? American Society for Bone and Mineral Research, #M-113, 2004.

Adler RA, Hertel CA, Williams MI, Petkov VI: Osteoporosis: a silent epidemic in male veterans. American Society for Bone and Mineral Research, #SA-365, 2004.

Lynn H, Lau E, Barrett-Connor, Nevitt M, Cauley J, Adler RA, Orwoll E: An evaluation of osteoporosis diagnostic tools for elderly Caucasian and Chinese men. American Society for Bone and Mineral Research #SU-394, 2004.

Geusens P, Hochberg MC, Adler RA: Performance of the OST risk tool for identifying men at increased risk of osteoporosis. *Ann Rheum Dis* 63(Suppl 1): 464, 2004.

Adler RA, Williams MI, Petkov, VI: Electronic reminders improve osteoporosis diagnosis and treatment in men, Department of Veterans Affairs Health Services Research and Development Annual Meeting, 2005.

Adler RA, Petkov VI, Wright S, Williams MI: ISCD male screening recommendations vs. OST. International Society for Clinical Densitometry Annual Meeting, 2005.

Petkov VI, Adler RA: Should age determine DXA sites in men? International Society for Clinical Densitometry Annual Meeting, 2005.

Stern AG, Petkov VI, Rao TPS, Disler D, Carlson P, Adler RA: Forearm bone density in patients with hand osteoarthritis. International Society for Clinical Densitometry Annual Meeting, 2005.

Petkov VI, Via PS, Williams MI, Adler RA: Adherence to oral bisphosphonates in men, Endocrine Society Annual Meeting 2005.

Ryan CS, Petkov VI, Adler RA: Osteoporosis in men: Value of laboratory testing. American Society for Bone and Mineral Research #SA380, 2005.

Adler RA, Ryan CS, Petkov VI: Implications of a T-score of -2.5 in men ages 50-65. American Society for Bone and Mineral Research #M301, 2005.

Petkov VI, Williams MI, Ryan CS, Adler RA: Men with osteoporosis discovered by the osteoporosis self-assessment tool: Are they different from other men with osteoporosis? American Society for Bone and Mineral Research #M302, 2005.

Guyer JL, Williams MI, Petkov VI, Adler RA: Effects of concomitant statin therapy in bisphosphonate treated patients with osteoporosis. American Society for Bone and Mineral Research #M366, 2005.

Petkov VI, Williams MI, Via PS, Adler RA: Persistence and compliance with oral bisphosphonates in men with osteoporosis, Endocrine Society 2006.

Holmes AK, Petkov VI, Adler RA: Osteoporosis Screening in Men: Adding Smoking Status to OST, American Society for Bone and Mineral Research, #SU279, 2006.

Williams MI, Adler RA: Prolonged suppression of bone resorption marker by zoledronic acid in osteoporosis, American Society for Bone and Mineral Research, #M336, 2006.

Adler RA, Samaropoulos X, Williams MI, Petkov VI: Longitudinal changes in bone density and management in men with osteopenia. American Society for Bone and Mineral Research #T266, 2007.

Via PS, Petkov VI, Adler RA: Long term retention of knowledge from an osteoporosis education program. American Society for Bone and Mineral Research #T337, 2007.

Recknor C, Adler RA, Casas N, Devogelaer J-P, Warner M, See K, Wong M, Krohn K: BMD response to teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. American College of Rheumatology 2007.

Krohn K, Adler RA, Devogelaer JP, Recknor C, See K, Wong M, Agnusdei D: Effects of glucocorticoid dose on the BMD response to teriparatide or alendronate therapy. International Glucocorticoid-Induced Osteoporosis Symposium, 2007.

Reid DM, Devogelaer J-P, Saag K, Roux C, Lau CS, Reginster J-Y, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink M: A single infusion of zoledronic acid 5 mg (ZOL) is significantly better than daily oral risedronate 5 mg (RIS) in increasing bone mineral density of the lumbar spine (LS), hip, femoral neck and trochanter in patients with glucocorticoid induced osteoporosis (GIO), Endocrine Society Annual Meeting #OR14-2, 2008

Adler RA: Osteoporosis Update, Endocrine Society Annual Meeting #N4-1, 2008.

Saag KG, Zanchetta JR, Devogelaer JP, Adler R, Eastell R, See K, Dalsky GP, Krohn K, Krege JH, Warner MR: Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results. American College of Rheumatology Annual Meeting, 2008.

Johnson D, Williams MI, LaFleur J, Adler RA: Zoledronic acid treatment of osteoporosis: effects in men. American Society for Bone and Mineral Research Annual Meeting, #Su238, 2008.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, See K, Dalsky GP, Krohn K, Krege JH, Warner MR: Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results. American Society for Bone and Mineral Research Annual Meeting, #1171, 2008.

Adler RA: Treatment threshold in men on androgen deprivation therapy: T-score vs. FRAX. American Society for Bone and Mineral Research Annual Meeting #F/S308, 2008.

Adler RA, Qutubuddin A, Carne WF, Kasturi G: Does vertebroplasty lead to osteoporosis diagnosis and/or treatment? International Society for Clinical Densitometry Annual Meeting, 2009

Adler RA, Munagala PR, Prakash A, Samaropoulos X, Petkov VI, Williams MI: What is the value of repeat DXA in men with osteopenia? Endocrine Society Annual Meeting, #P2-218, 2009.

Orwoll E, Miller P, Adachi J, Brown J, Adler R, Kendler D, Bucci-Rechtweg C, Rennie A, Mesenbrink P, Weinstein R. Once-yearly i.v. zoledronic acid 5 mg versus weekly oral alendronate 70mg in men with osteoporosis. Endocrine Society Annual Meeting, #OR13-3, 2009.

Adler RA, Pogach L, Semla T, Cunningham F: Comparison of GIOP treatment with other osteoporosis treatment in the U.S. Veterans Affairs System, 6th International Congress on Glucocorticoid-Induced Osteoporosis, 2009.

Adler RA, Munagala PR, Prakash A, Williams MI, Petkov VI: Can FRAX using hip DXA eliminate need for spine and forearm testing in men? American Society for Bone and Mineral Research, #SA283, 2009.

Adler RA, Semla T, Cunningham F, Pogach L: Baseline Treatment of Osteoporosis and Fracture in the Department of Veterans Affairs: Plan for Response to Treatment Algorithm, American Society for Bone and Mineral Research, 2010.

Moayyeri A, Adams JE, Adler RA, Blake GM, Krieg M-A, Hans D, Compston J, Lewiecki ME. Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis, submitted to IOF-ECCEO11, 2011.

LaFleur J, Ginter T, Hayden C, DuVall SL, Adler R, Nebeker J. Bone mineral density screening and osteoporosis rates in veterans, American Society for Bone and Mineral Research, 2011.

LaFleur J, DuVall SL, Ginter T, Yao Y, Hayden C, Adler R, Nebeker J. Natural language processing (NLP) technology – descriptively relevant in extracting bone mineral density (BMD) in screening results from radiology reports in the Veterans Affairs (VA) healthcare system, submitted to AHRQ, 2011.

Anderson A, Taylor J, McNamee S, Adler R. Anterior pituitary dysfunction in veterans with blast injury – a pilot study. Endocrine Society Annual Meeting, 2012.

LaFleur J, Smith J, Nelson S, Nelson R, Adler RA, Nebeker JR, Malone DC. Cost-effectiveness analysis of strategies for fragility fracture prevention in U. S. male veterans, Value in Health 15(4):A8. Presented at International Society for Pharmacoeconomics and Outcomes Research, June 2012.

Kazis LE, Lee A, Li M, LaFleur J, Vlad SC, Carey K, Chew P, Chandler D, Yurgin N, Adler RA. Predictors of non-adherence to bisphosphonates for male veterans with osteoporosis and/or osteoporotic fracture: importance of mental health conditions, American Society for Bone and Mineral Research Annual Meeting, #SU0381, 2012.

Desai K, Petkov VI, Adler RA. Can fracture risk calculators help determine bone density testing intervals in men? American Society for Bone and Mineral Research Annual Meeting, #SA-0301, 2012.

Gorgey AS, Adler RA, Khalil R, Gater DR. Femoral bone marrow adiposity in men with motor complete spinal cord injury, submitted to FASEB, 2012.

LaFleur J, Ginter T, Curtis JR, Adler RA, Agodoa I, Stolshek B, Nelson R, DuVall, SL. A novel method for obtaining bone mineral densities from a dataset of radiology reports and clinic notes: Natural language processing in a national cohort of postmenopausal veterans, American Society of Bone and Mineral Research Annual Meeting, 2013

LaFleur J, DuVall SL, Curtis JR, Adler RA, Willson T, Agodoa I, Stolshek B, Nelson RE. Association between bisphosphonate switching behavior and cost outcomes in postmenopausal United States veterans, American College of Rheumatology Annual Meeting, 2013.

Taylor JS, Anderson AD, McNamee S, Adler RA. Anterior pituitary dysfunction in male military veterans exposed to blast traumatic brain injury, Endocrine Society Annual Meeting, 2014.

Mazziotti G, Maffezzoni F, Doga M, Hofbauer LC, Adler RA, Giustina A. Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone-active drugs, Endocrine Society Annual Meeting, 2014.

Balasubramanian A, Wade SW, Adler RA, Lin C, Maricic M, O'Malley CD, Saag K, Curtis J. Glucocorticoid exposure and fracture risk in a large cohort of commercially-insured rheumatoid arthritis patients under age 65, American Society for Bone and Mineral Research Annual Meeting, 2014 and American College of Rheumatology Annual Meeting 2014 (oral presentation).

Bhat, N, Gill RS, Adler RA. Real world experience with clomiphene citrate for men with functional secondary hypogonadism, Endocrine Society Annual Meeting 2016, #SU201.

Colon-Emeric C, Adler R, Lyles K, LaFleur J, Pieper C. Determinants of osteoporosis screening in men, American Geriatrics Society Annual Meeting 2016.

Lewiecki EM, Adler R, Curtis J, Gagel R, Saag K, Singer A, Siris E, Wright NC, Yun H, Steven PM. Hip fractures and declining DXA testing: at a breaking point? American Society for Bone and Mineral Research 2016 Meeting, Oral presentation #1077.

Hall R, Sloane R, Adler R, Lyles K, LaFleur J, Colon-Emeric C. Kidney function and fracture risk among older male veterans. American Society for Bone and Mineral Research 2016 Meeting, #FR0235 and SA0235 (plenary poster).

Colon-Emeric C, LaFleur J, Lyles K, Adler R, Van Houtven C, Pieper C. Determinants of osteoporosis screening in men. American Society for Bone and Mineral Research 2016 Meeting, # MO0236.

LaFleur J, Cheng Y, Crook J, Adler R, Lyles K, Colon-Emeric C. Regional variations in rates of osteopenia, osteoporosis, fractures, and bone mineral density screening in Male US veterans. American Society for Bone and Mineral Research 2016 Meeting, #SA0221.

Colon-Emeric C, Pieper C, Van Houtven C, Lyles KW, LaFleur J, Grubber J, Adler R. Impact of osteoporosis screening on fractures and mortality in older U.S. men. American Geriatrics Society 2017 Meeting, #B89 (Presidential Poster Session).

Colon-Emeric C, Lyles KW, Pieper C, Van Houtven C, LaFleur J, Adler, RA. Impact of primary osteoporosis screening in a national sample of older men. American Society for Bone and Mineral Research 2017 Meeting, # MO0171.

Colon-Emeric C, Pieper C, Lyles K, VanHouten C, LaFleur J, Adler R. Primary osteoporosis screening in U.S. male veterans is effective in high risk subgroups but not overall. American Society for Bone and Mineral Research 2017 Meeting # LB-SU0373.

VanCott AC, Pugh MJ, Adler RA, Tortorice K, Gidal BE, Cunningham F. Fracture risk and bone health in veterans treated for epilepsy. American Academy of Neurology #1634, 2017.

Cirigliaro CM, Gorgey AS, Bauman WA, Adler RA. Estimates of precision of total and regional soft tissue body composition by dual-energy x-ray absorptiometry in persons with chronic spinal cord injury, International Society for Clinical Densitometry, 2018.

Colon-Emeric C, Sloane R, Lyles KW, Pieper C, Lee R, Adler RA. Age thresholds for primary osteoporosis screening in men. American Geriatrics Society, 2018. Plenary oral presentation (top 3 abstracts).

Gorgey AS, Khalil RE, Castillo T, Lavis T, Adler RA. Testosterone replacement therapy with and without resistance training may decrease visceral adiposity in men with spinal cord injury, International Spinal Cord Injury Society, 2018.

Bedoya P, Adler RA, Chong A, Gill RS. Opioid Induced Pituitary Dysfunction. Endocrine Society Annual Meeting, Abstract SU488, 2019.

Nguyen L, Adler R. Prediction of Atypical Fractures in Osteoporosis Patients Treated with Bisphosphonates or Denosumab: Does single energy imaging using the Hologic bone densitometer detect early AFF? Virginia Geriatrics Society, 2019 (Third place award).

Nguyen L, Adler RA. A tool to improve adherence to anti-resorptive therapy: Using single energy images at time of DXA to reassure patients: Pilot project in a predominantly male population. American Society for Bone and Mineral Research, Abstract SU795, 2019.

Ogunwale A, Colon-Emeric C, Sloane R, Adler RA, Lyles K, Lee R. Cholinesterase inhibitor use is associated with lower fracture risk in men with dementia. American Society for Bone and Mineral Research, Abstract 1074 (oral), 2019.

Bedoya P, Adler RA, Chong A, Gill RS. Opioid induced pituitary dysfunction. ENDO 2020, Abstract SUN-488, 2020.

BOOKS AND/OR CHAPTERS:

Witorsch RJ, Dave J, Adler RA: Prolactin receptors: The status of knowledge and current concepts concerning the mechanisms of action of prolactin. IN: Kalimi MY, Hubbard JR /Eds, Peptide Hormone Receptors, Berlin, New York: Walter deGruyter, pp. 63-127, 1987.

Schmitt JK, Adler RA: Endocrine-Metabolic consequences of Spinal cord Injury. In: Ozer M, Schmitt JK, Eds, Physical Medicine and Rehabilitation: State of the Art Reviews, Volume I, Philadelphia. Hanley & Bellfus, Inc., pp 424-441, 1987.

Adler RA: Prevention and treatment of steroid-induced osteoporosis. In: Rosen CJ, ed, Osteoporosis in Clinical Medicine: Principles and Practices, Totowa, NJ, The Humana Press, pp 239-250, 1996.

Gentili A, Adler RA: Growth hormone replacement in older men. eMedicine, 2001; revised 2005.

Gentili A, Adler RA, Henry CL, Schalch DS: Vitamin E toxicity. eMedicine, 2006.

Adler RA, editor: Osteoporosis – Pathophysiology and Clinical Management, Second edition, Humana/Springer, 2010.

Adler, RA: Osteoporosis in Men, in Adler, RA ed., Osteoporosis – Pathophysiology and Clinical Management, Humana/Springer, 2010, pages 545-557.

Adler RA, Curtis J, Saag K, Weinstein R: Glucocorticoid-induced osteoporosis, in Osteoporosis, 3rd Edition, R Marcus, D Feldman, D Nelson, C Rosen, editors, 2008, pages 1135-1166.

Adler RA, guest editor: Osteoporosis in the male patient, Clinical Cornerstone 8: (Suppl 3), 2006.

Adler RA, Binkley N: Quantitative ultrasound diagnosis of osteoporosis in men, in Osteoporosis in Men, 2nd Edition, E Orwoll, J Bilezikian, D Vanderschueren, eds., Elsevier, 2010, pages 541-546.

Binkley N, Adler RA: Dual-energy x-ray absorptiometry (DXA) in men, in *Osteoporosis in Men*, 2nd Edition, E Orwoll, J Bilezikian, D Vanderschueren, eds, Elsevier, 2010, pages 525-540.

Graham P, Adler RA, Bonner FJ, Kasturi G: The Prevention and Treatment of Osteoporosis, Chapter 39, in *DeLisa's Physical Medicine and Rehabilitation: Principles and Practice* 5th Edition, WR Frontera Ed, Lippincott, Philadelphia, pages 979-1014, 2010.

Adler RA: Normocalcemic hyperparathyroidism, in *Endocrine Essentials – Endocrine Update for General Medicine*, Anawalt BD, ed, Endocrine Society, Chevy Chase, MD, pages 48-53, 2012.

Adler RA, Weinstein RS, Saag KG: Glucocorticoid-induced osteoporosis, in *Osteoporosis*, 4th Edition, R Marcus, D Feldman, DW Dempster, M Luckey, JA Cauley Eds, Academic Press, pages 1191-1223, 2013.

Adler RA: Male Osteoporosis, in *Osteoporosis – Diagnosis and Management*, Stovall D, ed, Oxford: Wiley-Blackwell, 2013.

Adler RA, Giustina A: Parathyroid hormone and glucocorticoid-induced osteoporosis, in *The Parathyroids*, 3rd edition, J Bilezikian, R Marcus, S Silverberg, M Levine, C Marcocci, eds, Academic Press, 2014.

Orwoll ES, Adler RA: Osteoporosis in Men, in JP Bilezikian, Editor-in-Chief, *ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 9th edition, 2019.

Saag, K, Adler RA: Glucocorticoid-induced osteoporosis, in JP Bilezikian, Editor-in-Chief, *ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 9th edition, 2019.

Adler RA: Osteoporosis in men (Chapter 20), in BZ Leder and MN Wein, eds. *Osteoporosis – Pathophysiology and Clinical Management*, 3rd Edition, Humana Press, 2020

Adler RA, Assaad, MA, El-Hajj Fuleihan, G: Long-term bisphosphonate treatment: continuation and interruption, in Dempster D, Editor in Chief, *Osteoporosis 2020*.

Saag KG, Adler RA, Weinstein RS: Glucocorticoid-induced osteoporosis and Cushing syndrome in Dempster D, Editor in Chief, *Osteoporosis 2020*.

Adler RA: Osteoporosis in Men in Feingold KR et al eds, *Endotext*, 2020. PMID 32515917

OTHER:

Adler RA: Endocrine and metabolic effects of alcohol. In: Alcohol use and its medical consequences, A comprehensive slide teaching program for biomedical education. TimoniumMD: Millner-Fenwick, Inc., 1982.

Adler RA: Pituitary adenomas and oral contraceptives. *Lancet*, 2: 1384, 1978. (Letter)

Smith RP, Adler RA: Hazards of urine-reagent and preservation tablets. *Veterinary and Human Toxicology*, 22: 120-121, 1080. (Letter)

Gutman J, Adler RA: Estrogens and Calcitonin in post-menopausal women with hyperparathyroidism. *Annals of Internal Medicine*, 101: 283, 1984. (Letter)

Strong S, Adler RA: Why we need post-tenure review. *VCU Voice*, 24: (16)4, April 8, 1996.

Adler RA: Osteoporosis in women and men. In Prous Telesymposium, *Towards a Healthier Old Age*, 1999.

Adler RA: Thyroid dysfunction in the elderly. In Prous Telesymposium, *Towards a Healthier Old Age*, 1999.

Adler RA: Hormone replacement therapy in older women. In Prous Telesymposium, *Towards a Healthier Old Age*, 1999.

Adler RA: Hypogonadism in older men: Should it be diagnosed and treated? In Prous Telesymposium, *Towards a Healthier Old Age*, 1999.

Adler, RA: Review of "Glucocorticoid-Induced Osteoporosis" edited by A. Giustina, A. Angeli, and E. Canalis, for *Trends in Endocrinology*, 2003.

Adler RA: Answer to question on use of testosterone for osteoporosis in men, *J Musculoskeletal Medicine*, November 2003, pp 491-492.

Adler RA: Review of "Osteoporosis" by RC Hamdy and EM Lewiecki, *The Journal of Rheumatology*, 2014.

Lee DB, Adler RA, Gagel RF: Treatment of osteoporosis is not futile. *BMJ* 351:h3274, 2015.

RECENT AND UPCOMING INVITED PRESENTATIONS:

January 9-10, 2018: FDA Panel on Testosterone, College Park, MD

February 2, 2018: McGuire VAMC Medical Grand Rounds: Osteoporosis Update

March 2, 2018: McGuire VAMC Geriatrics Grand Rounds: Testosterone Update

March 18, 2018: Endocrine Nurses Society, Chicago, IL: Update on testosterone replacement in men

March 20, 2018: Endocrine Society Annual Meeting, ENDO 2018, Chicago, IL: Meet the professor: Osteoporosis in Men

March 28, 2018: Brown University Endocrine Grand Rounds, Providence, RI: Osteoporosis in Men

April 21, 2018: International Osteoporosis Foundation Meeting, Krakow, Poland: The National Bone Health Alliance and Post-Fracture Care

April 28, 2018: Virginia Geriatrics Society, Richmond, VA: Update on testosterone replacement in older men

June 12, 2018: Bone ECHO Program: Drug Holidays

June 25, 2018: NASA Bone Expert Panel Teleconference

July 5, 2018: Fragility Fracture Network Meeting, Dublin, Ireland: The ASBMR Strategic Roadmap to Improve Post-Fracture Care.

September 12, 2018: Second International Conference on Controversies in Vitamin D, Monteriggioni, Italy: Value of observational/association studies of Vitamin D

October 10, 2018: Prescribers' Letter Webinar: Glucocorticoid-Induced Osteoporosis

October 30-31, 2018: NIH Pathways to Prevention Workshop: Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention, Bethesda, MD: Atypical Femoral Fractures.

November 10, 2018: Mid-Atlantic Chapter of American Association of Clinical Endocrinologists Annual Meeting: Osteoporosis Treatment Options, Hyattsville, MD

January 11, 2019: McGuire VAMC Geriatrics Grand Rounds: A Pragmatic Approach to Treating Osteoporosis

January 16, 2019: FDA Review Panel on Romosozumab for Osteoporosis

March 27, 2019: VCU Endocrine Grand Rounds, Osteoporosis Update

April 26-28, 2019: Virginia Geriatrics Society: Vitamin D and Osteoporosis Treatment

June 29, 2019: VCU Women's Health 2019: Emerging Concepts in Bone Health, Norfolk, VA

July 22, 2019: NIH Pathways to Prevention Follow-Up Meeting, Bethesda, MD

August 1-2, 2019: Endocrine and Medical Grand Rounds, Dartmouth-Hitchcock Medical Center, Lebanon, NH

September 10-12, 2019: Third International Conference on Controversies in Vitamin D, Gubbio, Italy. (Session moderator, organizing committee)

September 25, 2019: Osteoporosis in Spinal Cord Injury Guidelines Committee, Denver, CO

December 5, 2019: Long-Term Treatment of Osteoporosis, American Society for Bone and Mineral Research Webinar.

September 23-25, 2020: Fourth International Conference on Controversies in Vitamin D, Pisa, Italy (virtual)

February 19-20, 2021: Skeletal Endocrinology Meeting (9th Edition, Virtual): Bisphosphonates and the Cardiovascular System

May 7, 2021: The Challenges of Osteoporosis Treatment, Texas Medical Center, Houston, TX.